Galvus (Vildagliptin) vs Placebo in Combination With Metformin and Insulin

Summary

The main objective is to show that the addition of Galvus versus placebo in patients with type 2 diabetes treated with metformin (at the maximum tolerated dose) and basal insulin properly titrated, allows a greater proportion of patients achieving an HbA1c below 7%. The primary efficacy endpoint was the percentage of patients responding to treatment (HbA1c less than 7%) after 3 months of treatment with Galvus or placebo

Timeline

Start

2011-12

Primary completion

2015-03

Completion

2015-03

Drugs

Indications